title: Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
abstract: Human immunodeficiency virus (HIV)-associated facial lipoatrophy (FLA) represents a common and highly stigmatizing side effect of retroviral therapy. By causing loss of subcutaneous adipose tissue mainly in the cheek, temple and periocular area, FLA can significantly affect the patient's quality of life, both physically and psychologically. A limited quantity of data has been published on various filling substances for the management of FLA. Here, the authors present two patients with HIV-associated FLA successfully treated with a novel HA filler over a period of 24 months.
authors.affiliation: Department of Dermatology, Ludwig-Maximillians-University, Munich, Germany. Tatjana.Pavicic@med.uni-muenchen.de
authors.forename: Tatjana
authors.initials: T
authors.lastname: Pavicic
authors.forename: Thomas
authors.initials: T
authors.lastname: Ruzicka
authors.forename: Hans-Christian
authors.initials: HC
authors.lastname: Korting
authors.forename: Gerd
authors.initials: G
authors.lastname: Gauglitz
mesh_terms: D000328:Adult; D003432:Cross-Linking Reagents / Q000008:administration & dosage*; D005145:Face; D015658:HIV Infections / Q000150:complications*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000628:therapy*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged
chemical_list: D003432:Cross-Linking Reagents; D006820:Hyaluronic Acid